 |
| |
| May-21-19 | Reiterated |
H.C. Wainwright |
Buy |
$12 → $9 |
|
| May-21-19 | Downgrade |
Raymond James |
Strong Buy → Outperform |
$11 → $5 |
|
| May-21-19 | Downgrade |
Cowen |
Outperform → Market Perform |
$13 → $3 |
|
| Dec-03-18 | Reiterated |
Cantor Fitzgerald |
Overweight |
$22 → $24 |
|
| Nov-15-18 | Initiated |
Raymond James |
Strong Buy |
$10 |
|
| Sep-07-18 | Initiated |
Piper Jaffray |
Overweight |
|
|
| Oct-24-17 | Initiated |
Guggenheim |
Buy |
$12 |
|
| Jul-26-17 | Initiated |
H.C. Wainwright |
Buy |
$10 |
|
| Jul-12-17 | Reiterated |
Cantor Fitzgerald |
Overweight |
$35 → $21 |
|
| Jun-23-17 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| Feb-10-17 | Initiated |
Cantor Fitzgerald |
Overweight |
$35 |
|
| Nov-15-16 | Reiterated |
RBC Capital Mkts |
Outperform |
$30 → $32 |
|
| Aug-11-16 | Initiated |
JMP Securities |
Mkt Outperform |
|
|
| Feb-17-16 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Oct-23-15 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| Aug-13-15 | Initiated |
Morgan Stanley |
Overweight |
$24 |
|
| Aug-05-15 | Initiated |
Nomura |
Buy |
$46 |
|
| Apr-08-15 | Reiterated |
RBC Capital Mkts |
Outperform |
$50 → $48 |
|
| Mar-11-15 | Reiterated |
RBC Capital Mkts |
Outperform |
$35 → $50 |
|
| Mar-11-15 | Reiterated |
Oppenheimer |
Outperform |
$42 → $49 |
|
|
|
| Aug-15-19 10:15PM | Edited Transcript of OCUL earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents |
| Aug-14-19 11:56AM | Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Simply Wall St. -5.99% |
| Aug-07-19 06:15PM | Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates Zacks |
| 04:01PM | Ocular Therapeutix Reports Second Quarter 2019 Financial Results and Business Update Business Wire |
| Jul-30-19 10:38AM | Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for Zacks |
| Jul-26-19 08:00AM | Ocular Therapeutix Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services Business Wire +11.21% |
| Jul-18-19 06:26PM | Allergan Announces FDA Acceptance of Glaucoma Candidate NDA Zacks |
| Jul-11-19 04:05PM | Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire |
| 04:01PM | Ocular Therapeutix Announces Christopher White as Senior Vice President, Head of Business and Corporate Development Business Wire |
| Jul-09-19 08:00AM | Ocular Therapeutix Announces Patricia Kitchen as Chief Operations Officer Business Wire |
| Jul-08-19 08:42AM | Implied Volatility Surging for Ocular (OCUL) Stock Options Zacks |
| Jul-01-19 08:00AM | Ocular Therapeutix Announces Commercial Launch of DEXTENZA® (dexamethasone intracanalicular insert) 0.4 mg for Ophthalmic Use in the United States Business Wire |
| Jun-24-19 08:50AM | Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza Zacks |
| Jun-23-19 03:53PM | Bulls And Bears Of The Week: Tyson, Tesla, Crocs And More Benzinga |
| Jun-21-19 11:19AM | FDA OKs Expanded Indication For Ocular Therapeutix Eye Pain Drug Months Ahead Of Schedule Benzinga +7.02% |
| 08:00AM | Ocular Therapeutix Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery Business Wire |
| Jun-10-19 07:15PM | Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $112,400 of Shares GuruFocus.com |
| 09:53AM | Does Market Volatility Impact Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Share Price? Simply Wall St. |
| May-31-19 08:44AM | Options Traders Expect Huge Moves in Ocular (OCUL) Stock Zacks +17.89% |
| May-30-19 08:00AM | Ocular Therapeutix to Present at Three Upcoming Investor Conferences Business Wire -5.38% |
| May-29-19 08:00AM | Ocular Therapeutix Announces Receipt of C-Code and Pass-Through Payment Status for DEXTENZA® Business Wire |
| May-23-19 11:26PM | Edited Transcript of OCUL earnings conference call or presentation 10-May-19 12:30pm GMT Thomson Reuters StreetEvents -7.17% |
| May-21-19 05:36PM | Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint Zacks -22.55% |
| 01:00PM | Raymond James Downgrades Ocular Therapeutix, Remains Bullish On Pipeline Benzinga |
| May-20-19 11:55PM | Chevron, Sprint, Ocular Therapeutix, and More: Why These Stocks Are in the Spotlight Insider Monkey |
| 04:05PM | Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma Business Wire |
| May-10-19 08:45AM | Ocular Therapeutix (OCUL) Reports Q1 Loss, Tops Revenue Estimates Zacks |
| 07:37AM | Ocular Therapeutix: 1Q Earnings Snapshot Associated Press |
| 07:30AM | Ocular Therapeutix Reports First Quarter 2019 Financial Results and Business Update Business Wire |
| May-03-19 10:30AM | Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for Zacks |
| May-02-19 08:00AM | Ocular Therapeutix To Report First Quarter 2019 Financial Results Business Wire |
| May-01-19 08:30AM | Ocular Therapeutix Announces DEXTENZA® (dexamethasone ophthalmic insert) Recommended for Unique J-Code by CMS Business Wire |
| Apr-30-19 08:00AM | Ocular Therapeutix, Inc. Settles Litigation with Mati Therapeutics, Inc. Business Wire |
| Apr-24-19 08:00AM | Ocular Therapeutix to Present New Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium Business Wire |
| Apr-23-19 04:55PM | Ocular Therapeutix Reports Changes to Board of Directors Business Wire +5.46% |
| Apr-03-19 08:00AM | Ocular Therapeutix to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire |
| Apr-02-19 08:15AM | Ocular Therapeutix Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery Business Wire |
| Mar-26-19 11:51AM | Recro Pharma Falls as FDA Denies Approval to Pain Candidate Zacks |
| Mar-25-19 08:00AM | Ocular Therapeutix Reports Election of Leslie Williams to Board of Directors Business Wire |
| Mar-21-19 09:00AM | Ocular Therapeutix to Host 2019 Research & Development Day Business Wire |
| Mar-14-19 09:34AM | Edited Transcript of OCUL earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents |
| Mar-07-19 08:35PM | Ocular Therapeutix Inc (OCUL) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 04:01PM | Ocular Therapeutix Reports Fourth Quarter and Year End 2018 Financial Results and Business Update Business Wire |
| Mar-05-19 08:00AM | Ocular Therapeutix to Present at the Cowen and Company 39th Annual Health Care Conference Business Wire |
| Mar-01-19 08:00AM | Ocular Therapeutix To Report Fourth Quarter and Year End 2018 Financial Results Business Wire |
| Feb-22-19 02:40PM | Watch These Four Biotech Stocks Friday ACCESSWIRE +15.24% |
| Feb-21-19 09:25PM | Ocular Therapeutix Prices $37.5 Million Subordinated Convertible Debt Financing Business Wire |
| Feb-20-19 08:30AM | Ocular Therapeutix Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD) Business Wire |
| Feb-06-19 12:30PM | Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) A Financially Sound Company? Simply Wall St. |
| Jan-22-19 07:40AM | Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys What Drives Growth in Today's Competitive Landscape GlobeNewswire |
| Jan-11-19 10:32AM | Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza Zacks |
| 08:38AM | The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA Benzinga |
| Jan-10-19 04:01PM | Ocular Therapeutix Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery Business Wire |
| Jan-07-19 09:00AM | Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain Business Wire |
| Dec-28-18 08:00AM | Ocular Therapeutix Announces Completion of Debt Refinancing Business Wire +6.72% |
| Dec-26-18 10:56AM | Edited Transcript of OCUL earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents |
| Dec-20-18 11:00AM | Are Insiders Buying Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock? Simply Wall St. |
| 08:00AM | Ocular Therapeutix Added to Nasdaq Biotechnology Index Business Wire |
| Dec-06-18 08:00AM | Ocular Therapeutix Announces the Hiring of Chad Brines, Vice President, Sales Business Wire +8.20% |
| Dec-04-18 08:59AM | Options Traders Expect Huge Moves in Ocular Therapeutix (OCUL) Stock Zacks |
| Dec-03-18 08:23AM | CORRECTING and REPLACING Ocular Therapeutix Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery Business Wire -13.96% |
| Nov-21-18 08:00AM | Ocular Therapeutix to Present at the 30th Annual Piper Jaffray Healthcare Conference Business Wire |
| Nov-15-18 06:35PM | H.C. Wainwright Sees over 80% Upside Potential for These Three Biotech Stocks SmarterAnalyst +5.95% |
| Nov-12-18 07:40AM | Recent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
| Nov-07-18 06:35PM | Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates Zacks |
| 05:36PM | Ocular Therapeutix: 3Q Earnings Snapshot Associated Press |
| 04:01PM | Ocular Therapeutix Reports Third Quarter 2018 Financial Results and Business Update Business Wire |
| Oct-31-18 08:00AM | Ocular Therapeutix To Report Third Quarter 2018 Financial Results Business Wire |
| Oct-30-18 10:33AM | Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know Zacks -5.08% |
| Oct-22-18 02:54PM | Ocular Therapeutix (OCUL): ReSure Warning Letter Insignificant to Pipeline, Says Analyst SmarterAnalyst |
| Oct-19-18 08:09AM | Ocular Therapeutix stock drops 10% after FDA warning letter MarketWatch |
| 07:50AM | Ocular Therapeutix Receives FDA Warning Letter Related to ReSure® Sealant Business Wire |
| Oct-18-18 08:55AM | Investor Expectations to Drive Momentum within Teradata, Liberty TripAdvisor, CPI Card Group, Cara Therapeutics, Ocular Therapeutix, and G-III Apparel Group, LTD Discovering Underlying Factors of Influence GlobeNewswire |
| Oct-11-18 12:57PM | Who Owns Ocular Therapeutix Inc (NASDAQ:OCUL)? Simply Wall St. |
| Oct-10-18 04:26PM | Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX) SmarterAnalyst -5.62% |
| Sep-26-18 08:00AM | Ocular Therapeutix to Present at the 2018 Cantor Global Healthcare Conference Business Wire |
| Sep-11-18 10:11AM | Edited Transcript of OCUL earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents |
| Sep-10-18 12:36PM | Here's Why Ocular Therapeutix Jumped 21.6% in August Motley Fool |
| Aug-29-18 08:00AM | Ocular Therapeutix to Present at the H.C. Wainwright 20th Annual Global Investment Conference Business Wire |
| Aug-27-18 08:30AM | Factors of Influence in 2018, Key Indicators and Opportunity within Lindblad Expeditions, Milacron, Lantheus, RCI Hospitality, Ingles Markets, and Ocular Therapeutix New Research Emphasizes Economic Growth GlobeNewswire |
| Aug-21-18 07:15PM | Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $119,000 of Shares GuruFocus.com |
| Aug-20-18 01:00PM | JMP Highlights Two Biotech Stocks to Consider Ahead of Upcoming FDA Decisions: Trevena (TRVN), Ocular (OCUL) SmarterAnalyst |
| Aug-07-18 05:20PM | Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates Zacks |
| 04:17PM | Ocular Therapeutix: 2Q Earnings Snapshot Associated Press |
| 04:00PM | Ocular Therapeutix Reports Second Quarter 2018 Financial Results and Business Update Business Wire |
| Jul-31-18 04:00PM | Ocular Therapeutix To Report Second Quarter 2018 Financial Results Business Wire |
| Jul-19-18 08:00AM | Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for DEXTENZA® Business Wire |
| 05:53AM | Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy? Zacks |
| Jul-18-18 07:26AM | Ocular Therapeutix (OCUL) Enters Oversold Territory Zacks |
| Jun-29-18 08:00AM | Ocular Therapeutix Announces NDA Resubmission of DEXTENZA Business Wire -6.90% |
| Jun-22-18 07:55AM | Report: Developing Opportunities within Mercantile Bank, Kindred Healthcare, Ocular Therapeutix, Roper Technologies, Milacron, and First Defiance Financial Future Expectations, Projections Moving into 2018 GlobeNewswire |
| Jun-12-18 08:00AM | Ocular Therapeutix to Present at the 2018 JMP Securities Life Sciences Conference Business Wire +6.34% |
| May-29-18 10:24AM | 5 Clinical-Stage Biotech Stocks to Buy Under $10 InvestorPlace |
| May-14-18 09:52PM | Edited Transcript of OCUL earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents |
| May-08-18 05:10PM | Ocular Therapeutix: 1Q Earnings Snapshot Associated Press |
| 04:01PM | Ocular Therapeutix Reports First Quarter 2018 Financial Results and Business Update Business Wire |
| May-03-18 08:38AM | Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension Business Wire |
| 07:45AM | Investor Expectations to Drive Momentum within Quaker Chemical, Ocular Therapeutix, Viad, Ingredion, LivePerson, and Tableau Software Discovering Underlying Factors of Influence GlobeNewswire |
| Apr-27-18 08:00AM | Ocular Therapeutix to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Business Wire |
| Apr-26-18 04:01PM | Ocular Therapeutix to Report First Quarter 2018 Financial Results Business Wire |
|
|
|
|
| Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant for the treatment of wet age-related macular degeneration(AMD); and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. Its various preclinical programs include OTX-BPI for the treatment of acute ocular pain; OTX-BSI to treat post-operative Pain, and inflammation and bacterial infection; OTX-KTO for the treatment of allergy; and OTX-CSI to treat chronic dry-eye. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds to address conditions of the eye. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Notman Donald | Chief Financial Officer | Jun 14 | Buy | 4.33 | 2,500 | 10,825 | 24,049 | Jun 17 07:21 PM | | Williams Leslie J. | Director | Jun 14 | Buy | 4.40 | 4,500 | 19,800 | 4,500 | Jun 17 07:21 PM | | Sawhney Amarpreet | Chairman of the Board | Jun 07 | Buy | 3.02 | 65,468 | 197,713 | 1,056,031 | Jun 10 04:55 PM | | Sawhney Amarpreet | Chairman of the Board | Jun 06 | Buy | 2.80 | 59,000 | 165,200 | 990,563 | Jun 10 04:55 PM | | Mattessich Antony C. | President & CEO | Jun 06 | Buy | 2.81 | 40,000 | 112,400 | 97,900 | Jun 10 04:53 PM | | Sawhney Amarpreet | Chairman of the Board | Jun 05 | Buy | 2.91 | 32,852 | 95,599 | 931,563 | Jun 06 06:09 PM | | Sawhney Amarpreet | Chairman of the Board | Jun 04 | Buy | 2.92 | 12,928 | 37,750 | 898,711 | Jun 06 06:09 PM | | Goldstein Michael H. | Chief Medical Officer | May 28 | Buy | 2.51 | 12,000 | 30,120 | 25,686 | May 30 04:10 PM | | Heier Jeffrey S. | Director | Mar 15 | Buy | 4.15 | 24,000 | 99,600 | 24,000 | Mar 18 06:20 PM | | Goldstein Michael H. | Chief Medical Officer | Mar 15 | Buy | 4.15 | 10,000 | 41,500 | 13,686 | Mar 18 06:20 PM | | LINDSTROM RICHARD L MD | Director | Mar 13 | Buy | 4.33 | 56,441 | 244,390 | 100,000 | Mar 14 04:14 PM | | Hanley Kevin F. | See Remarks | Dec 14 | Buy | 5.50 | 10,000 | 55,000 | 20,000 | Dec 18 08:52 AM | | Hanley Kevin F. | SEE REMARKS | Dec 10 | Buy | 5.60 | 10,000 | 56,000 | 10,000 | Dec 12 04:35 PM | | Bollag Daniel M | See Remarks | Dec 06 | Buy | 5.76 | 17,400 | 100,224 | 42,100 | Dec 10 04:15 PM | | Mattessich Antony C. | President & CEO | Aug 20 | Buy | 5.95 | 20,000 | 119,000 | 57,900 | Aug 21 04:30 PM |
|
|
|
|
|
|
